Abstract:Aim: To improve an asialoglycoprotein receptor (ASGPR)-based enrichment method for detection of circulating tumor cells (CTCs) of hepatocellular carcinoma (HCC). Methods: Peripheral blood samples were collected from healthy subjects, patients with HCC or various other cancers, and patients with hepatic lesions or hepatitis. CTCs were enriched from whole blood by extracting CD45-expressing leukocytes with monoclonal antibody coated-beads following density gradient centrifugation. The remaining cells were cytocentrifuged on polylysine-coated slides. Isolated cells were treated by triple immunofluorescence staining with CD45 antibody and a combination of antibodies against ASGPR and carbamoyl phosphate synthetase 1 (CPS1), used as liver-specific markers, and costained with DAPI. The cell slide was imaged and stained tumor cells that met preset criteria were counted. Recovery, sensitivity and specificity of the detection methods were determined and compared by spiking experiments with various types of cultured human tumor cell lines. Expression of ASGPR and CPS1 in cultured tumor cells and tumor tissue specimens was analyzed by flow cytometry and triple immunofluorescence staining, respectively. Results: CD45 depletion of leukocytes resulted in a significantly greater recovery of multiple amounts of spiked HCC cells than the ASGPR(+) selection (Ps < 0.05). The expression rates of either ASGPR or CPS1 were different in various liver cancer cell lines, ranging between 18% and 99% for ASGPR and between 9% and 98% for CPS1. In both human HCC tissues and liver cancer cell lines, there were a few HCC cells that did not stain positive for ASGPR or CPS1. The mixture of monoclonal antibodies against ASGPR and CPS1 identified more HCC cells than either antibody alone. However, these antibodies did not detect any tumor cells in blood samples spiked with the human breast cancer cell line MCF-7 and the human renal cancer cell line A498. ASGPR(+) or/and CPS1(+) CTCs were detected in 29/32 (91%) patients with HCC, but not in patients with any other kind of cancer or any of the other test subjects. Furthermore, the improved method detected a higher CTC count in all patients examined than did the previous method (P = 0.001), and consistently achieved 12%-21% higher sensitivity of CTC detection in all seven HCC patients with more than 40 CTCs. Conclusion: Negative depletion enrichment combined with identification using a mixture of antibodies against ASGPR and CPS1 improves sensitivity and specificity for detecting circulating HCC cells.

Detection of circulating hepatocellular carcinoma cells with SSX gene mRNA as tumor marker

Detection of Circulating Hepatocellular Carcinoma Cells with SSX Gene Mrna As Tumor Marker

Expression of Cancer-Testis Antigen SSX1 Gene Mrna in Hepatocellular Carcinoma

Heparanase mRNA expression and point mutation in hepatocellular carcinoma

Expression of cancer-testis antigen in hepatocellular carcinoma

Use of Cancer-Testis Antigen Mrna As Specific Markers to Evaluate the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation

Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and Α-Fetoprotein

A Blood-Based 22-Gene Expression Signature for Hepatocellular Carcinoma Identification

Detection of AFP Mrna in Peripheral Blood of Patients with Hepatocellular Carcinoma and Its Significance

Α-Fetoprotein Mrna Detection in Peripheral Blood and Bone Marrow in Patients with Hepatocellular Carcinoma and Its Sigificance

Diagnostic value of cancer-testis antigen mRNA expression in peripheral blood of patients with small hepatocellular carcinoma

Genes Expression Profiling of Peripheral Blood Cells of Patients with Hepatocellular Carcinoma

EXPRESSION OF HEPATOCELLULAR CARCINOMA ANTIGEN587 IN HUMAN HEPATOCELLULAR CARCINOMA AND ITS BIOINFORMATICS ANALYSIS

The Expression of Cancer-Testis Antigen MAGE-A1、MAGE-C2 and SSX-1 Mrna in Hepatocellular Carcinoma

Detection of Alpha-fetoprotein mRNA in Peripheral Blood of Patients with Primary Hepatocellular Carcinoma by RT-PCR

Circulating markers for prognosis of hepatocellular carcinoma.

Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation

Expression of HSP7O and MHC-I antigen in hepatocellular carcinoma and its significance

Improved method increases sensitivity for circulating hepatocellular carcinoma cells

Screening and Analysis of Differentially Expressed Genes in Human Hepatocellular Carcinoma Using Suppression Subtractive Hybridization

SOX4 as biomarker in hepatitis B virus-associated hepatocellular carcinoma